Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities

Storey, Susan; Ah, Diane Von; Hammer, Marilyn J.

doi:10.1188/17.onf.e141-e151

Cited by 17 publications

(10 citation statements)

References 67 publications

(200 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Factors contributing to hyperglycaemia in cancer patients include physiologic stress, glycemic status (glucose intolerance, diagnosed with diabetes, diagnosed with pre-diabetes, or unknown diabetes status), administration of glucocorticoids, and changes in nutrition and activity [3]. Cancer and diabetes mellitus share common risk factors: older age, male sex, obesity, lack of physical activity, a high-calorie diet, tobacco smoking, and insulin resistance, all of which can lead to hyperglycaemia.…”

Section: Discussionmentioning

confidence: 99%

“…Hyperglycaemia also heightens the risk for the development and progression of cancer, affects diagnostic imaging studies, attenuates the immune system, and increases resistance to chemotherapy [3]. The cancer-specific death rate tends to rise with mean fasting glucose level.…”

Section: Introductionmentioning

confidence: 99%

“…Recent evidence strongly suggests that prolonged exposure to hyperglycaemia can epigenetically modify gene expression profiles in human cells, and that this effect is sustained even after glycemic control is achieved therapeutically (this phenomenon is called hyperglycemic memory) [6]. In cancer patients, hyperglycaemia frequently occurs independently of the diagnosis of diabetes [3].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions

et al. 2019

View full text Add to dashboard Cite

IntroductionMortality rates from various cancer types are higher in patients with hyperglycaemia-associated pathologies. Among antineoplastics for treating pancreatic carcinoma, doxorubicin was found to be top of the list for inducing hyperglycaemia-related adverse drug reactions.MethodsIndividual case safety reports of doxorubicin-induced hyperglycaemia-related adverse drug reactions (HG-ADRs) submitted during the period 2000–2017 were extracted from VigiBase®. Factors influencing outcome seriousness in these cases were analyzed using bivariate correlation and logistical regression. Age was stratified into five groups.ResultsAmong the 558 cases with high blood glucose included in this study, with an average patient age of 55.9 ± 14.3 years, 71.1% had serious outcomes and 10.9% died. Three factors—died, age, and gender—were all found to be significantly correlated with outcome seriousness (P < 0.01), while five factors—year reported, ADR duration, latency, treatment duration, and dosage—showed no correlation with outcome seriousness (P > 0.05). Identical conclusions were reached upon analyzing only the cases that did not involve corticosteroid use.ConclusionAge and gender are risk factors for doxorubicin-induced serious HG-ADRs; males and older patients are more likely to suffer a serious outcome following such a reaction.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions

et al. 2019

View full text Add to dashboard Cite

show abstract

“…For example, patients with AML who experienced hyperglycemia were found to have a greater risk for infection, (19, 41), sepsis, (42), longer hospital length of stay (18) and mortality. However, inconsistencies in definitions and measurement practices between studies make it difficult to interpret the full impact of hyperglycemia on health outcomes(43). …”

Section: Comorbidities and Amlmentioning

confidence: 99%

Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia

2017

Self Cite

View full text Add to dashboard Cite

Purpose of review To describe the pathology, impact of comorbidities, functional limitations, symptoms, and quality of life (QOL) related to treatment of acute myeloid leukemia (AML) in older adults. Recent findings AML is a rare aggressive hematologic disease that occurs most often in older adults. The prognosis for older patients with AML is markedly worse due to genetic mutations and patient characteristics such as comorbidities and functional limitations. Patient characteristics may influence treatment decisions, as well as impact symptoms, functional ability, health-related outcomes and (QOL). Summary As the population continues to age, the number of people diagnosed with AML is expected to increase. Better management of comorbidities is imperative to improving QOL and other treatment related outcomes. Prospective, longitudinal and multi-site studies are warranted to further understand the interaction between these characteristics on symptoms, outcomes and QOL.

show abstract

“…Hyperglycemia has been shown to promote both tumorigenesis and tumor progression via diverse mechanisms and has also been found to be an adverse prognostic factor for several malignancies. [6][7][8][9] In addition, hyperglycemia has been demonstrated to affect surgical treatment outcomes and has been strongly associated with the development of postoperative complications. [10][11][12][13] Despite this mounting evidence, limited data are available regarding the relationship between hyperglycemia and OSCC clinicopathologic manifestations and treatment outcomes.…”

mentioning

confidence: 99%

Influence of Hyperglycemia on Treatment Outcomes of Oral Cavity Squamous Cell Carcinoma

Lien

Padua

Tay

et al. 2020

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

The present study investigated the association between perioperative hyperglycemia and the treatment and survival outcomes of patients with oral cavity squamous cell carcinoma (OSCC). Patients and Methods: From 2004 to 2016, 385 patients with OSCC were enrolled and stratified into normoglycemic (<180 mg/dL) and hyperglycemic ($180 mg/dL) groups. The clinicopathologic characteristics and treatment outcomes of OSCC were subsequently analyzed. Results: Of the 385 patients, 61 (15.8%) were in the hyperglycemic group. Hyperglycemia was significantly associated with pT stage, pN stage, overall pathologic stage, extranodal extension, albumin level, and tumor depth (P = .004, P = .042, P = .008, P = .001, P = .004, and P = .011, respectively). Patients with hyperglycemia also required a longer hospital stay (P = .003). The 5-year overall survival and diseasespecific survival were poorer in the hyperglycemic group than in the normoglycemic group (P = .001 and P = .002, respectively). Multivariate analysis revealed that hyperglycemia is a significant adverse prognostic indicator for OSCC (hazard ratio, 1.709; 95% confidence interval, 1.003 to 2.912; P = .049). Conclusions: Hyperglycemia is associated with more advanced disease and poorer survival rates in patients with OSCC. It correlates with adverse clinicopathologic characteristics and longer hospital stay. Screening for hyperglycemia and maintenance of normal glycemic status during the treatment course is imperative in the treatment of OSCC.

show abstract

Measurement of Hyperglycemia and Impact on Health Outcomes in People With Cancer: Challenges and Opportunities

Cited by 17 publications

References 67 publications

Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions

Risk Factors for Doxorubicin-Induced Serious Hyperglycaemia-Related Adverse Drug Reactions

Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia

Influence of Hyperglycemia on Treatment Outcomes of Oral Cavity Squamous Cell Carcinoma

Contact Info

Product

Resources

About